It was billed as a transformative deal that would drive a transformative company. And it happened just two years ago. Founded in 2003, Sublimity Therapeutics, a Dublin drug development company, had already raised around €38 million to finance the advancement of a treatment for ulcerative colitis. Then in May 2018, the company announced that it was raising a further €55 million from a host of heavy-hitting investors. It was, according to Anthony J Giovinazzo, an industry veteran installed as executive chairman at the time of the 2018 deal, an “important milestone” for the company, which was previously known as Sigmoid…

Want to continue reading?

Celebrate with us – 7 years of The Currency

Unlock full access to The Currency and The Wall Street Journal with an annual membership and receive a FREE Samsonite Spectrolite Briefcase – worth €175 delivered to your door.

Subscribe

Cancel at any time.

Are you already a member? .